Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Claes Held

Showing results (131-140 of 227) with videos related to

Pageof 23
Sort By:
European Heart Journal. Cardiovascular Pharmacotherapy|December 13, 2022
Design and rationale of randomized evaluation of decreased usage of beta-blockers after acute myocardial infarction (REDUCE-AMI)Troels Yndigegn, Bertil Lindahl, Joakim Alfredsson, et al.
Journal of the American College of Cardiology|October 2, 2012
Factors contributing to the lower mortality with ticagrelor compared with clopidogrel in patients undergoing coronary artery bypass surgeryChristoph Varenhorst, Ulrica Alström, Benjamin M Scirica, et al.
Journal of the American Heart Association|September 16, 2017
Sex Differences in Clinical Characteristics, Psychosocial Factors, and Outcomes Among Patients With Stable Coronary Heart Disease: Insights from the STABILITY (Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy) TrialPatricia Oliveira Guimarães, Christopher B Granger, Amanda Stebbins, et al.
Clinical Chemistry|November 5, 2016
Growth Differentiation Factor 15 Predicts All-Cause Morbidity and Mortality in Stable Coronary Heart DiseaseEmil Hagström, Claes Held, Ralph A H Stewart, et al.
Journal of the American Heart Association|December 17, 2015
Efficacy and Safety of Vorapaxar in Non-ST-Segment Elevation Acute Coronary Syndrome Patients Undergoing Noncardiac SurgerySean van Diepen, Pierluigi Tricoci, Mohua Podder, et al.
Journal of the American College of Cardiology|October 27, 2022
Biomarker-Based Prediction of Recurrent Ischemic Events in Patients With Acute Coronary SyndromesGorav Batra, Johan Lindbäck, Richard C Becker, et al.
Journal of the American College of Cardiology|September 30, 2017
Physical Activity and Mortality in Patients With Stable Coronary Heart DiseaseRalph A H Stewart, Claes Held, Nermin Hadziosmanovic, et al.
JAMA Network Open|September 16, 2020
Evaluation of the Age, Biomarkers, and Clinical History-Bleeding Risk Score in Patients With Atrial Fibrillation With Combined Aspirin and Anticoagulation Therapy Enrolled in the ARISTOTLE and RE-LY TrialsZiad Hijazi, Jonas Oldgren, Johan Lindbäck, et al.
The New England Journal of Medicine|April 8, 2024
Beta-Blockers after Myocardial Infarction and Preserved Ejection FractionTroels Yndigegn, Bertil Lindahl, Katarina Mars, et al.
Circulation|November 22, 2019
Patients With Atrial Fibrillation Taking Nonsteroidal Anti-Inflammatory Drugs and Oral Anticoagulants in the ARISTOTLE TrialFrederik Dalgaard, Hillary Mulder, Daniel M Wojdyla, et al.
Pageof 23

Showing results (131-140 of 227) with videos related to

Sort By:
Pageof 23
European Heart Journal. Cardiovascular Pharmacotherapy|December 13, 2022
Design and rationale of randomized evaluation of decreased usage of beta-blockers after acute myocardial infarction (REDUCE-AMI)Troels Yndigegn, Bertil Lindahl, Joakim Alfredsson, et al.
Journal of the American College of Cardiology|October 2, 2012
Factors contributing to the lower mortality with ticagrelor compared with clopidogrel in patients undergoing coronary artery bypass surgeryChristoph Varenhorst, Ulrica Alström, Benjamin M Scirica, et al.
Journal of the American Heart Association|September 16, 2017
Sex Differences in Clinical Characteristics, Psychosocial Factors, and Outcomes Among Patients With Stable Coronary Heart Disease: Insights from the STABILITY (Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy) TrialPatricia Oliveira Guimarães, Christopher B Granger, Amanda Stebbins, et al.
Clinical Chemistry|November 5, 2016
Growth Differentiation Factor 15 Predicts All-Cause Morbidity and Mortality in Stable Coronary Heart DiseaseEmil Hagström, Claes Held, Ralph A H Stewart, et al.
Journal of the American Heart Association|December 17, 2015
Efficacy and Safety of Vorapaxar in Non-ST-Segment Elevation Acute Coronary Syndrome Patients Undergoing Noncardiac SurgerySean van Diepen, Pierluigi Tricoci, Mohua Podder, et al.
Journal of the American College of Cardiology|October 27, 2022
Biomarker-Based Prediction of Recurrent Ischemic Events in Patients With Acute Coronary SyndromesGorav Batra, Johan Lindbäck, Richard C Becker, et al.
Journal of the American College of Cardiology|September 30, 2017
Physical Activity and Mortality in Patients With Stable Coronary Heart DiseaseRalph A H Stewart, Claes Held, Nermin Hadziosmanovic, et al.
JAMA Network Open|September 16, 2020
Evaluation of the Age, Biomarkers, and Clinical History-Bleeding Risk Score in Patients With Atrial Fibrillation With Combined Aspirin and Anticoagulation Therapy Enrolled in the ARISTOTLE and RE-LY TrialsZiad Hijazi, Jonas Oldgren, Johan Lindbäck, et al.
The New England Journal of Medicine|April 8, 2024
Beta-Blockers after Myocardial Infarction and Preserved Ejection FractionTroels Yndigegn, Bertil Lindahl, Katarina Mars, et al.
Circulation|November 22, 2019
Patients With Atrial Fibrillation Taking Nonsteroidal Anti-Inflammatory Drugs and Oral Anticoagulants in the ARISTOTLE TrialFrederik Dalgaard, Hillary Mulder, Daniel M Wojdyla, et al.
Pageof 23